Drugs / 89Zr-daratumumab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03665155 | Sep 2018 → Apr 2020 | plasma cell myeloma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 89Zr-daratumumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03665155 ↗ |
| Modality | Monoclonal antibody | “89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody” NCT03665155 ↗ |
| Target | CD38 | “CD38-targeting monoclonal antibody” NCT03665155 ↗ |